Tercica Increlex Hypoglycemia Risk Mitigated By Dose Timing, Titration – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA concerns over Tercica’s Increlex hypoglycemic seizure risk led to strengthened labeling on the need for dosing at meal time but were insufficient to warrant rejection of the extreme short stature therapy, agency review documents show.